FdaApplication
BLA 761416
Identifiers
- fda_app_no: BLA761416
Properties
| Property | Value |
|---|---|
| applicant_name | Jazz Pharmaceuticals Ireland Limited |
| application_type | BLA |
| approval_date | 2024-11-20 |
Revenue by product
ZIIHERA
| Period | Revenue |
|---|---|
| Q2 2026 | $15.4M |
| Q1 2026 | $13.3M |
| Q4 2025 | $8.5M |
| Q3 2025 | $8.3M |
| Q2 2025 | $6.0M |
| Q1 2025 | $2.0M |
| Q4 2024 | $1.1M |
| Q3 2024 | $0.0M |
| Q2 2024 | $0.0M |
| Q1 2024 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZIIHERA | ZANIDATAMAB-HRII | 300MG | For Injection |
1 product